Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

In this randomized, placebo-controlled trial, investigators evaluated the effects of the sodium–glucose cotransporter 2 inhibitor dapagliflozin in patients with heart failure and a reduced ejection fraction with or without type 2 diabetes. The risk of worsening heart failure or cardiovascular death...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The New England journal of medicine Ročník 381; číslo 21; s. 1995 - 2008
Hlavní autoři:	McMurray, John J.V, Solomon, Scott D, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, Sabatine, Marc S, Anand, Inder S, Bělohlávek, Jan, Böhm, Michael, Chiang, Chern-En, Chopra, Vijay K, de Boer, Rudolf A, Desai, Akshay S, Diez, Mirta, Drozdz, Jaroslaw, Dukát, Andrej, Ge, Junbo, Howlett, Jonathan G, Katova, Tzvetana, Kitakaze, Masafumi, Ljungman, Charlotta E.A, Merkely, Béla, Nicolau, Jose C, O’Meara, Eileen, Petrie, Mark C, Vinh, Pham N, Schou, Morten, Tereshchenko, Sergey, Verma, Subodh, Held, Claes, DeMets, David L, Docherty, Kieran F, Jhund, Pardeep S, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna-Maria
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Massachusetts Medical Society 21.11.2019
Témata:	Aged Antidiabetics Benzhydryl Compounds - adverse effects Benzhydryl Compounds - therapeutic use Cardiology and Cardiovascular Disease Cardiovascular Agents - therapeutic use Cardiovascular Diseases - mortality Clinical outcomes Clinical trials Combined Modality Therapy Congestive heart failure Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Drug dosages Drug therapy Drug Therapy, Combination Ejection fraction Evidence-based medicine Female Glucosides - adverse effects Glucosides - therapeutic use Glycated Hemoglobin A - analysis Heart failure Heart Failure - complications Heart Failure - drug therapy Hemoglobin Hospitalization Humans Hypoglycemia Intravenous administration Kaplan-Meier Estimate Kardiologi och kardiovaskulära sjukdomar Male Middle Aged Patient safety Renal function Sodium Sodium-glucose cotransporter Sodium-Glucose Transporter 2 Inhibitors - adverse effects Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Stroke Volume - drug effects Ventricular Dysfunction, Left - complications Ventricular Dysfunction, Left - drug therapy
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	In this randomized, placebo-controlled trial, investigators evaluated the effects of the sodium–glucose cotransporter 2 inhibitor dapagliflozin in patients with heart failure and a reduced ejection fraction with or without type 2 diabetes. The risk of worsening heart failure or cardiovascular death was lower among those who received dapagliflozin, regardless of the presence or absence of diabetes.
Bibliografie:	ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa1911303